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ortality Reduction by Implantable
ardioverter-Defibrillators in High-Risk
atients With Heart Failure, Ischemic Heart
isease, and New-Onset Ventricular Arrhythmia
n Effectiveness Study
aul S. Chan, MD,* Rodney A. Hayward, MD†‡
nn Arbor, Michigan
OBJECTIVES To investigate the generalizability of the reduction in mortality posed by implantable
cardioverter-defibrillators, we examined the effectiveness of defibrillators as applied in routine
medical practice.
BACKGROUND Implantable cardioverter-defibrillators have been shown to be efficacious in the primary and
secondary prevention of overall and cardiovascular mortality in clinical trials.
METHODS Using the National Veterans Administration database, we identified a cohort of 6,996
patients from 1995 to 1999 with new-onset ventricular arrhythmia and pre-existing ischemic
heart disease and congestive heart failure, of which 1,442 received a defibrillator, and followed
them for three years to determine rates of mortality. With multivariate logistic regression
analyses that adjusted for demographics, illness severity, and comorbidity, we assessed overall,
cardiovascular, and noncardiovascular rates of mortality. To further address potential
confounding, we also stratified the cohort by quintiles using a multivariable propensity score
for each patient and determined mortality rates.
RESULTS For the overall cohort, multivariate regression showed that those who received defibrillators
had significantly lower all-cause (odds ratio [OR] 0.52; 95% confidence interval [CI] 0.45 to
0.60) and cardiovascular (OR 0.56; 95% CI 0.49 to 0.65)] rates of mortality at three years. No
significant differences were noted between groups in their rates of noncardiovascular mortality
(OR 0.92; 95% CI 0.77 to 1.10). Propensity score analysis demonstrated similar mortality
reduction benefits at three years: risk ratio (RR) 0.72 (95% CI 0.69 to 0.79) for all-cause; RR
0.70 (95% CI 0.63 to 0.78) for cardiovascular; and RR 0.95 (95% CI 0.83 to 1.08) for
noncardiovascular rates of mortality. These results suggest that one death is prevented in this
patient population for every four to five patients receiving a defibrillator for three years.
CONCLUSIONS Implantable cardioverter-defibrillators in routine medical practice significantly reduce cardio-
vascular and all-cause rates of mortality at levels similar to secondary prevention
trials. (J Am Coll Cardiol 2005;45:1474–81) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.031Cardiology Foundation
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audden cardiac death is responsible for close to 50% of all
ardiovascular mortality (1,2). High-risk patients for sudden
ardiac death include those with ventricular arrhythmias,
schemic heart disease, and clinical heart failure with left
entricular dysfunction (3–5). Until recently, the prevention
f sudden cardiac death in this high-risk population has
nvolved the use of antiarrhythmic agents, with mixed results
6–9). In the past decade, several primary and secondary
revention trials have examined the role of implantable
ardioverter-defibrillators (ICDs) in preventing death
mong these high-risk patients (5,7,10–15).
From the *Division of Cardiology, University of Michigan School of Medicine;
VA Center for Practice Management and Outcomes Research, VA Ann Arbor
ealthcare System; and the ‡Departments of Internal Medicine and Health Man-
gement and Policy, University of Michigan Schools of Medicine and Public Health,
nn Arbor, Michigan.c
Manuscript received November 11, 2004; revised manuscript received January 1,
005, accepted January 11, 2005.Of the nine primary and secondary prevention trials, four
Multicenter Automatic Defibrillator Implantation Trial
MADIT], MADIT-II, Multicenter Unsustained Tachy-
ardia Trial [MUSTT], and Antiarrhythmics Versus Im-
lantable Defibrillators [AVID]) showed significant de-
reases in mortality and three (Canadian Implantable
efibrillator Study [CIDS], Cardiac Arrest Study Hamburg
CASH], and Defibrillators In Non-Ischemic Cardiomy-
pathy Treatment Evaluation [DEFINITE] trial) showed a
trong trend for ICDs in their primary end point of
ortality reduction (3). Two studies (Coronary Artery
ypass Graft Patch [CABG-PATCH] trial and Cardiomy-
pathy Trial [CAT]) demonstrated no benefit with ICD
herapy. However, despite evidence on meta-analyses that
CDs confer a survival benefit to this high-risk cardiovas-
ular population, it remains unclear whether these benefits
re generalizable to the larger population outside the strict
ontrolled setting of randomized trials (16,17). For example,
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May 3, 2005:1474–81 Mortality Reduction by ICDsn several of the primary prevention trials, patients had to
eet defined criteria of electrophysiologic inducibility or
bnormalities on signal-averaged electrocardiography. Pa-
ients with New York Heart Association functional class IV
ongestive heart failure or a history of ventricular fibrillation
VF) or cardiac arrest often were excluded as well. More-
ver, many of the centers enrolling patients into randomized
linical trials were tertiary care centers with high volumes
nd significant expertise in cardiovascular care and device
mplantation and monitoring. Patients were followed closely
nd frequently, with many aspects of their care optimized.
Therefore, we undertook an effectiveness study examin-
ng the use and benefits of ICDs within a large health care
ystem (the Veterans Administration). An effectiveness
tudy examines the benefits achieved in routine practice in a
iverse patient population and often has considerably
reater statistical power than clinical trials to discern bene-
ts in patient subgroups (17,18). To investigate the gener-
lizability of the mortality reduction observed in ICD
fficacy trials, we followed a defined cohort of patients with
ew-onset ventricular arrhythmia and both pre-existing
linical heart failure and ischemic heart disease for three
ears and examined the use of ICDs and the rates of
ll-cause and cardiovascular mortality.
ETHODS
e used the National Veterans Affairs (VA) database from
ustin, Texas, to identify all patients who were discharged
rom a VA hospital with a new-onset primary diagnosis of
entricular tachycardia (VT), VF, or cardiac arrest from
anuary 1, 1995, through December 31, 1999 (International
lassification of Diseases-Ninth Revision-Clinical Modifi-
ation [ICD-9-CM] codes 427.1, 427.41, and 427.5) and
efined discharge from this hospitalization as the index
ate. The study further required cohort patients to have
oth pre-existing ischemic heart disease (ICD-9-CM codes
10, 411, 412, 414.0, and 429.2 and ICD-9-CM procedure
odes 36.0, 36.1, and 36.2) and clinical heart failure diag-
oses (ICD-9-CM codes 428.0, 428.1, and 428.9) before
he index hospitalization. Defibrillator recipients were de-
ned as patients who received a device within 30 days of
ospital admission (ICD-9-CM procedure code 37.94).
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CI  confidence interval
ICD  implantable cardioverter-defibrillator
ICD-9-CM  International Classification of Diseases-
Ninth Revision-Clinical Modification
OR  odds ratio
RR  risk ratio
VA  Veterans Affairs
VF  ventricular fibrillation
VT  ventricular tachycardiaBecause the defibrillator group survived until device fmplantation, to avoid selection bias, we excluded patients
n the nondefibrillator group if they died before discharge.
e also excluded patients who had an acute myocardial
nfarction during the index hospitalization; who already had
defibrillator in place; or who had a history of VF, VT, or
ardiac arrest before the index hospitalization.
Potential confounders also were extracted from the Na-
ional VA outpatient and inpatient databases in Austin,
exas, including age, gender, baseline comorbid conditions
diabetes mellitus, hypertension, chronic obstructive pulmo-
ary disease, stroke, renal failure, peripheral vascular disease,
yperlipidemia, and obesity), medication data (diuretics,
eta-blockers, angiotensin-converting enzyme [ACE] in-
ibitors, angiotensin receptor blockades, statin agents, spi-
onolactone), type of index ventricular arrhythmia, history
f revascularization therapy (angioplasty, coronary bypass
urgery), frequency of hospitalization for the 12 months
efore the index date, and frequency of clinic visits for the
years before the index date.
Mortality rates were determined through the National
eath Index for all-cause and cardiovascular mortality at
ne-, two-, and three-year periods from the index date
19,20). For each patient, a social security number, date of
irth, first and last names, middle initial, and gender were
ubmitted to generate true matches. True matches were
efined as an exact match of all aforementioned six vari-
bles. Matches that were exact except for small variations
e.g., by one letter in name) were adjudicated by hand on a
linded basis, based on the National Death Index’s proba-
ility score for a true match. Analyses were conducted on a
e-identified dataset, and the study was approved by the
nn Arbor VA Institutional Review Board.
tatistical analysis. We used unadjusted analyses to com-
are rates of all-cause and cardiovascular mortality at one,
wo, and three years for the defibrillator and nondefibrillator
roups using cross-tabulation and the chi-square test and
eported the results as odds ratios (ORs) and 95% confi-
ence intervals (CIs).
We then used two-sample t tests to compare baseline
ovariates between the defibrillator and nondefibrillator
roups. Adjusted analyses were conducted using both mul-
ivariate logistic regression and propensity score analyses.
emographic and clinical variables were entered as inde-
endent variables, with age and defibrillator therapy in a
ultivariate stepwise forward logistic regression model (p
.05 for variable inclusion) to predict all-cause, cardiovas-
ular, and noncardiovascular rates of mortality. Variables in
he final regression models were reported as ORs with 95%
Is.
Because complete medication data were available only for
he cohort whose index date was on or after January 1, 1999,
e performed a separate comparison of baseline covariates
ncorporating comorbidity, medication, and demographic
ata for this subpopulation (the “1999 cohort”). These
ovariates were then entered in a multivariate stepwise
orward logistic regression model to predict mortality and
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Mortality Reduction by ICDs May 3, 2005:1474–81ere reported separately as ORs with 95% CI. A C-statistic,
epresenting the area under the curve (receiver-operator
urve) or how well the model is fitted, was reported for each
ultivariate regression model.
For each group, a predicted risk function was calculated
rom the regression model coefficients and the mean fre-
uencies of each covariate for each treatment group through
he logit function (21). From this, an absolute risk differ-
nce, lives saved per 100 treated, and a number needed to
reat were determined for all-cause and cardiovascular rates
f mortality.
Next, a propensity score analysis was performed for each
atient in the overall cohort and the 1999 cohort to further
ssess comparability of the two groups. This statistical
echnique examines factors influencing the likelihood of
eceiving treatment (in this case, ICD placement), allowing
or comparisons of more comparable patients. Using mul-
ivariate logistic regression, we used the potential confound-
rs listed as predictors (independent variables) for ICD
lacement (the dependent variable), with all variables re-
aining in the model regardless of level of statistical
ignificance (22,23). The full regression model was then
sed to generate the predicted probability of receiving an
CD for each patient (i.e., their “propensity score”), which
anges between 0 and 1.
The cohort was then subdivided into quintiles based on
he propensity score so that comparisons of patients with
imilar probabilities of receiving a defibrillator could be
ade (24). The distribution of all-cause, cardiovascular, and
oncardiovascular rates of mortality in the defibrillator and
ondefibrillator groups in each propensity score quintile was
ompared. Risk ratios (RRs) for mortality were calculated
or each propensity score quintile, as well as an overall
antel-Hantzel RR for this stratified analysis.
Statistical analyses were performed using SAS version 8.2
oftware (SAS Institute, Cary, North Carolina).
ESULTS
rom 1995 through 1999, 6,996 patients met inclusion
riteria for our cohort of patients with new-onset ventricular
rrhythmia in the setting of pre-existing ischemic heart
isease and clinical heart failure. Of these, 1,442 (20.6%)
eceived defibrillator therapy (ICD group). In the non-ICD
roup, 22 (0.4%) of the 5,554 patients subsequently received
CDs beyond 30 days of their index hospitalization but were
ept in the non-ICD group for analyses. Patients receiving
CDs were somewhat younger; more likely to have been
dmitted for heart failure, coronary artery disease, or any
ause for the year before the index hospitalization; to have
ad a previous myocardial infarction or angioplasty before
nrollment; to have hyperlipidemia; and to have had VT or
VF arrest as their index ventricular arrhythmia (Table 1).
atients who did not receive ICDs were more likely to have
omorbidities (stroke, chronic obstructive pulmonary dis-
ase, renal failure, peripheral vascular disease), to be on Ctandard of care medications for ischemic heart disease and
ongestive heart failure (for 1999 cohort), and to have had
cardiac arrest with undetermined rhythm diagnosis as their
ndex ventricular arrhythmia.
ortality results for the full cohort. Unadjusted all-cause
ates of mortality were lower in the ICD group: 13% versus
9% at one year (OR 0.37; 95% CI 0.31 to 0.43); 24%
ersus 43% at two years (OR 0.43; 95% CI 0.38 to 0.49);
nd 37% versus 55% at three years (OR 0.48; 95% CI 0.43
o 0.54). The improvement was most pronounced during
he first year but was sustained throughout the three years of
ollow-up. Unadjusted results also showed a lower
ardiovascular-specific rate of mortality in the ICD group:
% versus 20% at one year (OR 0.37; 95% CI 0.30 to 0.45);
6% versus 30% at two years (OR 0.45; 95% CI 0.39 to
.53); and 23% versus 36% at three years (OR 0.54; 95% CI
.47 to 0.62; Fig. 1).
Multivariate logistic regression showed that those who
eceived defibrillators had a survival advantage as compared
ith those who did not even after adjusting for age, baseline
omorbid conditions, hospitalization frequency the year
efore index date, revascularization history, and type of
resenting ventricular arrhythmia: OR 0.40 at one year
95% CI 0.33 to 0.48); OR 0.48 at two years (95% CI 0.41
o 0.55); and OR 0.52 at three years (95% CI 0.45 to 0.60;
-statistic [area under the receiver operator curve]  0.79).
urthermore, the mortality reduction benefit from ICDs
as derived almost entirely from its protective effect on
ardiovascular mortality: OR 0.38 at one year (95% CI 0.31
o 0.47); OR 0.48 at two years (95% CI 0.41 to 0.57); and
R 0.56 at three years (95% CI 0.49 to 0.65; C-statistic 
.71; Table 2). Mortality rates between the two groups from
oncardiovascular causes showed no significant differences
fter three years of follow-up (OR 0.92; 95% CI 0.77 to
.10).
The absolute risk reduction for three-year all-cause mor-
ality was 0.22, or 22 lives saved per 100 treated, producing
number needed to treat of 4.5 to avert one death with an
CD. Similarly, the absolute risk reduction for three-year
ardiovascular mortality was 0.24, or 24 lives saved per 100
reated, yielding a number needed to treat of 4.2 to avert one
ardiovascular death.
ortality results for the medication cohort. For the 1999
ohort, those for whom medication data were available,
esults were similar to those for the overall cohort (Table 2).
nadjusted all-cause mortality was significantly lower in the
CD group in all three years. Multivariate logistic regression
howed that those who received defibrillators continued to
ave a survival advantage as compared with those who did
ot. For all-cause mortality: OR 0.22 at one year (95% CI
.14 to 0.34); OR 0.28 at two years (95% CI 0.19 to 0.42); and
R 0.26 at three years (95% CI 0.18 to 0.39; C-statistic 
.84). For cardiovascular mortality: OR 0.28 at one year
95% CI 0.17 to 0.48); OR 0.38 at two years (95% CI 0.26
o 0.58); and OR 0.51 at three years (95% CI 0.36 to 0.73;
-statistic  0.70; Table 2).
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May 3, 2005:1474–81 Mortality Reduction by ICDsropensity score analysis. Propensity scores were calcu-
ated for each patient’s probability of treatment with a
efibrillator. The logistic regression model yielded a
-statistic of 0.76, indicating good discrimination in the
odel between those patients who received an ICD and
hose who did not. The predicted probability of receiving an
CD (i.e., propensity score) ranged from 0.7% to 99.7% for
he nondefibrillator group and 1.4% to 99.9% for the
efibrillator group.
All-cause mortality rates stratified by propensity score
uintiles revealed significantly lower three-year mortality
ates in the ICD group at the top three quintiles, where
Table 1. Baseline Characteristics for Cohort
Covariates Con
Age
Diabetes mellitus
Hypertension
Hyperlipidemia
Stroke
COPD
Renal failure
Morbid obesity
Peripheral vascular disease
CAD admission/past year 0
CHF admission/past year 0
Any admission/past year 1
Average clinic visits/py over 3 yr
History of previous myocardial infarction
History of previous angioplasty
History of previous CABG
Index ventricular tachycardia
Index ventricular fibrillation
Index cardiac arrest
For 1999
Covariates Con
ACE inhibitor usage
ARB usage
Beta-blocker usage
Statin usage
Sprionolactone usage
Diuretic usage
ACE  angiotensin-converting enzyme; ARB  angioten
CAD  coronary artery disease; CHF  congestive heart f
implantable cardioverter-defibrillator; py  per year.igure 1. Unadjusted cardiovascular and noncardiovascular rates of mortality (in %
ardioverter-defibrillator.ost patients receiving ICDs were distributed, and no
ifference in mortality rates in the lower two quintiles
Table 3). The Mantel-Hantzel RR for all five quintiles was
.72 (95% CI 0.66 to 0.79) for three-year all-cause mortality
nd RR 0.70 (95% CI 0.63 to 0.78) for cardiovascular
ortality (Table 3). Notably, the overall Mantel-Hantzel
R for rates of noncardiovascular mortality was 0.95
95% CI 0.83 to 1.08), suggesting that ICDs were not
ssociated with significant benefit for noncardiovascular rate
f mortality.
All-cause mortality rates for the 1999 medication cohort
tratified by propensity score quintiles derived from a
n  5,554) ICD (n  1,442) p Value
.6 66.2 0.02
.0% 33.1% 0.006
.4% 70.7% 0.64
.0% 33.6% 0.0001
.4% 8.3% 0.009
.5% 13.8% 0.0004
.4% 7.2% 0.0001
.2% 8.0% 0.008
.3% 16.4% 0.008
dmit/py 0.88 admit/py 0.0001
dmit/py 1.42 admit/py 0.0001
dmit/py 2.63 admit/py 0.0001
isit/py 16.3 visits/py 0.91
.2% 75.4% 0.0001
.9% 12.6% 0.0001
.2% 13.7% 0.12
.1% 93.1% 0.0001
.0% 21.2% 0.0001
.6% 11.3% 0.0007
rt Only
(n  662) ICD (n  227) p Value
.0% 40.1% 0.01
.0% 7.1% 0.59
.2% 28.6% 0.0007
.0% 29.1% 0.06
.8% 8.8% 0.66
.2% 41.0% 0.02
ceptor blocker; CABG  coronary artery bypass surgery;
COPD  chronic obstructive pulmonary disease; ICD trol (
68
37
71
26
10
17
10
10
19
.40 a
.79 a
.55 a
16.4 v
70
8
12
85
12
14
Coho
trol
50
6
41
36
9
50
sin re) by treatment group. CV cardiovascular mortality; ICD implantable
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Mortality Reduction by ICDs May 3, 2005:1474–81eparate multivariate propensity score analysis for this group
evealed similar significantly lower three-year mortality rates
n the ICD group at the top three quintiles, where most
atients were distributed (Table 3). A Mantel-Hantzel
tratified analysis of all five quintiles gave a RR of 0.54 (95%
I 0.44 to 0.67) for all-cause rate of mortality.
For the entire cohort, patients in the lowest two propensity
core quintiles (where no mortality differences were found)
ere older (mean age for quintile 1  72; quintile 3  68;
uintile 5  64), were more likely to have a cardiac arrest as
heir index arrhythmia, and were found to have significantly
igher rates of other comorbid conditions (Fig. 2). When
e then stratified the entire cohort on age (70 years, 70
ears), multivariate regression analysis for three-year all-
able 2. Summary of All-Cause and Cardiovascular Mortality Re
Control Event
Rate (%)
ICD
Rate
ll-cause mortality
1 year 1,633/5,554 (29) 191/1,4
3 year 3,038/5,554 (55) 530/1,4
ardiovascular mortality
1 year 1,099/5,554 (20) 119/1,4
3 year 1,996/5,554 (36) 335/1,4
ardiovascular mortality (1999 cohort)
1 year 134/662 (20) 18/22
3 year 241/662 (36) 56/22
I  confidence interval; ICD  implantable cardioverter-defibrillator; NNT  nu
Table 3. Stratified Analysis of Three Year Mo
Score Quintile
Quintile Control Event R
All-cause mortality
1 911/1,343 (
2 728/1,292 (
3 568/1,160 (
4 458/982 (47
5 373/777 (48
Cardiovascular mortality
1 536/1,343 (
2 492/1,292 (
3 381/1,160 (
4 328/982 (33
5 259/777 (33
Noncardiovascular mortality
1 375/1,343 (
2 236/1,292 (
3 187/1,160 (
4 130/982 (13
5 114/777 (15
All-cause mortality (1999 cohort)
1 87/165 (53
2 79/160 (49
3 93/142 (66
4 65/102 (64
5 64/93 (69)CI  confidence interval; ICD  implantable cardioverter-defibriause mortality gave an OR of 0.54 (95% CI 0.44 to 0.67)
or age 70 years and 0.46 (95% CI 0.38 to 0.55) for age
70 years. Because the mortality risk was higher in the70
ears’ group (58.1% vs. 44.2%), patients in this age group
erived the greatest benefit.
To further explore whether there were some subgroups
hat received significantly more or less benefit than average,
e examined interactions for key independent variables. No
ignificant interactions were found between defibrillator
enefit and any of the cardiac medications or revasculariza-
ion procedures, suggesting that the relative benefits of
efibrillators are additive with those received from beta-
lockers, ACE inhibitors, statins, angioplasty, and coronary
rtery bypass grafting. Similarly, no evidence exists that the
ion by ICDs From Multivariate Regression Analysis
t Unadjusted
OR
Adjusted OR
(95% CI)
Lives Saved
per 100 NNT
3) 0.37 0.40 (0.33 to 0.48) 25 4.0
7) 0.48 0.52 (0.45 to 0.60) 22 4.5
) 0.37 0.38 (0.31 to 0.47) 22 4.5
3) 0.54 0.56 (0.49 to 0.65) 24 4.2
0.34 0.28 (0.17 to 0.48) 22 4.5
0.57 0.51 (0.36 to 0.73) 14 7.1
needed to treat (calculated as 1/lives saved per 100); OR  odds ratio.
y for Overall and 1999 Cohorts by Propensity
%) ICD Event Rate (%) Risk Ratio (95% CI)
38/57 (67) 0.98 (0.81–1.19)
67/107 (63) 1.11 (0.95–1.30)
98/239 (41) 0.84 (0.71–0.99)
154/417 (37) 0.79 (0.69–0.91)
173/622 (28) 0.58 (0.50–0.67)
overall Mantel-Hantzel risk ratio: 0.72 (0.66–0.79)
20/57 (35) 0.88 (0.61–1.26)
40/107 (37) 0.98 (0.76–1.27)
52/239 (22) 0.66 (0.51–0.85)
101/417 (24) 0.73 (0.60–0.88)
122/622 (20) 0.59 (0.49–0.71)
overall Mantel-Hantzel risk ratio: 0.70 (0.63–0.78)
18/57 (32) 1.13 (0.76–1.67)
27/107 (25) 1.38 (0.98–1.95)
46/239 (19) 1.19 (0.89–1.60)
53/417 (13) 0.96 (0.71–1.29)
51/622 (8) 0.56 (0.41–0.76)
overall Mantel-Hantzel risk ratio: 0.95 (0.83–1.08)
6/13 (46) 0.88 (0.48–1.60)
7/18 (39) 0.79 (0.43–1.44)
12/36 (33) 0.51 (0.32–0.82)
35/76 (46) 0.72 (0.54–0.96)
29/84 (35) 0.50 (0.36–0.69)
overall Mantel-Hantzel risk ratio: 0.54 (0.44–0.67)duct
Even
(%)
42 (1
42 (3
42 (8
42 (2
(8)
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May 3, 2005:1474–81 Mortality Reduction by ICDsresence or absence of diabetes or other major comorbidities
odified relative treatment benefits.
A summary of the multivariate regression and propensity
core analyses for three-year mortality in the overall cohort
s given in Table 4. Because the outcome of interest
mortality) is not a rare event, the OR is not equivalent to
he RR. After adjusting for the frequency of the outcome
ariable, a Mantel-Hantzel OR also was computed for each
ropensity score analysis, thereby allowing for direct com-
arisons between the multivariate logistic regression and
ropensity score analyses. Both adjusted analyses give rela-
ively similar results, suggesting that there was sufficient
verlap in the distribution of covariates between patients in
oth groups to make good comparisons and avoid signifi-
ant selection bias.
ISCUSSION
his study found that those subjects who received ICDs had
ubstantially improved survival compared with similar high-
igure 2. Covariate distribution by propensity score quintile. Patients in t
or Q1, Q3, and Q5 of 72, 68, and 64, respectively) and have chronic obstr
Renal), morbid obesity, peripheral vascular disease (PVD), and an index a
TN hypertension; lipid hyperlipidemia; MImyocardial infarction
brillation; V. Tach  ventricular tachycardia; Q1  quintile 1; Q3  qu
able 4. Summary of Multivariate Regression and Propensity
core Analyses for Three-Year All-Cause, Cardiovascular, and
oncardiovascular Mortality in Overall Cohort
Mortality
Method of
Analysis
Three-Year OR
(95% CI)
ll-cause Logistic regression 0.53 (0.45–0.60)
Propensity score 0.63 (0.56–0.72)
ardiovascular Logistic regression 0.56 (0.49–0.65)
Propensity score 0.61 (0.53–0.70)
oncardiovascular Logistic regression 0.92 (0.77–1.10)
Propensity score 0.93 (0.78–1.11)pI  confidence interval; OR  odds ratio.isk patients (i.e., those with clinical heart failure, ischemic
eart disease, and new-onset ventricular arrhythmia) who
id not receive an ICD. The overall three-year all-cause
ortality risk reduction of 28% for the entire cohort
derived from Mantel-Hantzel RR of 0.72 for the ICD
roup) is consistent with the range of 20% to 54% from
revious randomized clinical trials. Moreover, the magni-
ude of this mortality reduction benefit from ICDs is
erived almost entirely from cardiovascular mortality risk
eduction, a finding that is similar to previous clinical trials
nd that is biologically plausible (3). Although a slight trend
as found for a 5% decrease in rates of noncardiovascular
ortality with defibrillator therapy from propensity score
nalyses, this finding was not statistically significant. The
-statistic from the regression models for three-year all-
ause mortality was 0.79 for the overall and 0.84 for the
999 cohorts, suggesting very good model discrimination
nd predictive ability, when compared with the commonly
ited gold standard, the Acute Physiology And Chronic
ealth Evaluation (APACHE) score (C-statistic  0.90)
25). These results suggest that the dramatic benefits found
n secondary prevention trials can be translated into tangible
enefits within a large healthcare system without a substan-
ial dilution of benefits due to poor generalizability or
election of patients in routine practice.
Adequate control for potential confounders is essential in
ohort studies, and we used two methods (multivariate
ogistic regression and propensity score analyses) to account
or patient illness severity. Multivariate logistic regression
odeling is useful in controlling for confounders and
est propensity score quintile (Q1) are more likely to be older (mean ages
pulmonary disease (COPD), diabetes mellitus (DM), stroke, renal failure
hmia of cardiac arrest (Arrest). CABG  coronary artery bypass grafting;
A percutaneous transluminal coronary angioplasty; V. Fib ventricular
3; and Q5  quintile 5 for propensity scores.he low
uctive
rrhytredicting an outcome but does not ensure that the study
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Mortality Reduction by ICDs May 3, 2005:1474–81roups truly overlap in disease severity, which can only be
erived from a careful analysis of the joint distribution of the
ovariates (22,23). However, propensity score analysis al-
ows a ready assessment of comparability of the two groups,
hich is greatly enhanced when the regression model has
ood discrimination and balances patient attributes in the
omparison quintiles, both of which were true in this study.
lthough residual confounding is an inherent threat to the
alidity of any observational study, the subclassification
ethod into quintiles using a valid propensity score has
een shown to remove 90% or more of the potential bias
resent when the two groups overlap (24,26,27). The
imilarity of our results in the logistic regression and
ropensity score analysis suggest that our findings are
tatistically robust and consistent.
It is notable that patients who received ICDs in the
owest two propensity score quintiles (where overall cardio-
ascular and noncardiovascular rates of mortality were high-
st) were least likely to derive mortality benefits. This is not
urprising, given that they were older, had a cardiac arrest as
heir index arrhythmia, and had higher frequencies of major
omorbidities, such as diabetes mellitus, chronic obstructive
ulmonary disease, stroke, peripheral vascular disease, and
enal failure. Subsequent analyses of the overall cohort
tratified by age 70 or 70 years showed that patients
70 years of age derived as much if not more absolute
enefit than those 70 years, a finding consistent with the
iterature. In contrast, those who received ICDs in the
ighest three quintiles had fewer major types of comorbidity
nd were more likely to have ventricular tachycardia as their
ndex arrhythmia. Our propensity score analysis, therefore,
uggests that patients who receive ICDs are most likely to
erive substantial overall and cardiovascular mortality re-
uction benefits when they have not had a cardiac arrest and
ave few other types of comorbidity besides those directly
ssociated with their ischemic heart disease and clinical
eart failure. Furthermore, these analyses suggest that this
ealth care system is doing a good job of selectively putting
efibrillators in those patients who are more likely to benefit
because 89% of defibrillators were placed in patients in the
igh-benefit quintiles), although considerable room also
xists for improvement (since at the time of the study, most
atients in the high-benefit quintiles had not received a
efibrillator).
The average number needed to treat for ICDs in this
ohort was 4.2 to prevent one cardiovascular death during a
hree-year period. Few therapies in all of medicine have
hown such striking benefits for overall survival. Certainly,
or most high-risk patients, the benefits of ICDs are likely
o be worth even the considerable costs of placing ICDs.
revious cost-effectiveness analysis from the MADIT-1
tudy showed that ICD therapy had an incremental cost-
ffectiveness ratio of $27,000/life-year saved, with a similar
umber needed to treat as our study (28). This ratio suggests
hat ICDs in this high-risk population would be cost-
ffective in routine practice, especially when patients have dollow-up periods longer than found in clinical trials.
owever, we should seek ways to improve the cost-
ffectiveness of ICD placement by exploring strategies of
tratifying at-risk patients using risk prediction tools. In
ddition, this study examined benefits in very high-risk
atients (those with clinical heart failure, ischemic heart
isease, and new-onset ventricular arrhythmia), and extrap-
lating these results to lower-risk patients would be specu-
ative at best.
Meta-analyses of ICD clinical trials suggest that ICDs
re effective in secondary prevention for all-cause mortality,
ith a RR 0.76 (95% CI 0.65 to 0.89) (3). The results from
ur study (RR reduction of 28%) are consistent with the
hree-year all-cause mortality risk reduction of 31% ob-
erved in the AVID trial and 24% observed in meta-analyses
f all three secondary prevention trials (7). In addition to
xamining efficacy in real-world circumstances, effectiveness
tudies often can provide better statistical precision, espe-
ially for subgroup analyses. In our study, the number of
efibrillator patients studied was greater than the number
ncluded in all three secondary prevention trials combined,
nd results were consistent across the population. Because
he use of beta-blockers, ACE inhibitors, and statins often
ere low in the earlier clinical trials, some have questioned
he benefits of ICDs when medication therapy is fully
ptimized (29). In our study, however, we had adequate
tatistical power to examine this question and found no
vidence that those on statins, ACE inhibitors, or beta-
lockers received less relative benefit.
tudy limitations. The major limitation of this study was
ts reliance on information that could be extracted from the
A’s electronic medical record. Data on some prognostic
utcome measures, such as detailed electrocardiography
nformation, ejection fraction, and some medications (e.g.,
igoxin and amiodarone), were unavailable. We used fre-
uency of hospitalization and clinic visits before the index
ate as surrogate severity measures, but we cannot be sure
hat these measures are sufficient for full case-mix adjust-
ent. As is true of all cohort studies, logistic regression and
ropensity score analyses can only reduce, but not eliminate,
he potential of selection bias influencing the results. How-
ver, the use of propensity scores and the excellent predic-
iveness of the regression models used are particular
trengths of our study. Our study cohort was almost
xclusively men with new-onset sustained ventricular ar-
hythmias and, thus, may not be generalizable to women or
rimary prevention of mortality by ICDs. Finally, the
stablished death databases are known to have some incom-
lete or inaccurate data. Still, sensitivity and specificity for
oncordance with death information from the National
eath Index has been found to be 94% to 98% and 100%,
espectively, when matched using the patient attributes used
n our study (social security number, first and last names,
iddle initial, date of birth, and gender) (20,30).
onclusions. We found that ICDs were associated with
ramatically lower all-cause and cardiovascular rates of
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May 3, 2005:1474–81 Mortality Reduction by ICDsortality in high-risk patients with ischemic heart disease,
ongestive heart failure, and new-onset ventricular arrhyth-
ia in a large nationwide health care system. These benefits
ccurred despite a high level of optimal medication man-
gement and were consistent throughout a diverse patient
opulation being cared for at dozens of different VA health
are facilities. These findings suggest that the mortality
eduction benefits with ICDs found in well-controlled
econdary prevention clinical trials can be successfully ex-
ended to high-risk patients in routine practice if adequate
ttention is given to health care quality and patient
election.
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